China Pharmaceutical Sector Report 2018 1st Quarter
An EMIS Insights Industry ReportEMIS is an ISI Emerging Markets Group Company Date: July 2018
Pages: 59
Available in: English
In the first two months of Q4 of 2017, the sales revenue of China’s pharmaceutical manufacturing sector went down by 17.8% y/y to RMB 445bn, as a result of the government’s tightening control over drug prices and distribution costs. Declines in revenues were posted by almost all of the subsectors – ready-prepared TCM, chemical API, biological medicines, medical equipment and instruments, as well as sanitary materials and supplies. In this period, the sector’s total profit dropped by 2.6% to RMB 60.5bn. In Q4 2017, industrial production of pharmaceutical and medicine products marked an increase of 10.4% y/y to 902,000 tonnes, while their sales volume rose by 3.7% y/y to 788,800 tonnes.
This report provides a complete and detailed analysis of the pharmaceutical sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.
What this report allows you to do:
- Understand the key elements at play in the pharmaceutical sector in China
- Access forecasts for growth in the sector
- View key data on production and sales for the sector in China
- Crystallise the forces both driving and restraining this sector in China
- Build a complete perspective on sector trade, investment and employment
- Understand the competitive landscape and who the major players are
- View M&A activity and major deals
- Gain an understanding of the regulatory environment for the sector in China
- Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine)
See below for a complete table of report contents:
Email us at: emisstoresupport@emis.com